Tamibarotene + Placebo + Azacitidine
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndromes
Conditions
Myelodysplastic Syndromes
Trial Timeline
Feb 8, 2021 → Nov 13, 2024
NCT ID
NCT04797780About Tamibarotene + Placebo + Azacitidine
Tamibarotene + Placebo + Azacitidine is a phase 3 stage product being developed by Syros Pharmaceuticals for Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT04797780. Target conditions include Myelodysplastic Syndromes.
What happened to similar drugs?
7 of 18 similar drugs in Myelodysplastic Syndromes were approved
Approved (7) Terminated (6) Active (7)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04797780 | Phase 3 | Terminated |
Competing Products
20 competing products in Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| JSP191 | Jasper Therapeutics | Phase 1 | 11 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 14 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 35 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 35 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 35 |
| decitabine + decitabine | Eisai | Phase 2 | 35 |
| decitabine + azacitidine | Eisai | Approved | 35 |
| Decitabine | Eisai | Phase 2 | 27 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 29 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 35 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 21 |
| Decitabine | Eisai | Phase 2 | 35 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 32 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 24 |
| Decitabine | Johnson & Johnson | Phase 2 | 35 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 27 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 35 |